Probiotic Therapeutics
Biogut Technologies is a pioneering biotech company dedicated to revolutionizing healthcare through innovative probiotic therapeutics. At Biogut, we're harnessing the power of synthetic biology and advanced peptide engineering to develop cutting-edge probiotic formulations equipped with a guided-missile peptide system.
Our probiotic therapeutics are engineered to precisely target and eliminate specific pathogenic bacteria and cancer cells with unparalleled precision and efficacy. By incorporating a guided-missile anti-microbial or anti-cancer peptide system, our products can deliver therapeutic payloads directly to the desired targets, minimizing off-target effects and maximizing treatment outcomes.
With a focus on precision medicine, Biogut's probiotic therapeutics offer a promising avenue for personalized treatment strategies tailored to individual patients. Whether combating infectious diseases caused by pathogenic bacteria or addressing cancer at its source, our innovative approach holds tremendous potential for improving patient outcomes and quality of life.
“ Biogut is committed to pushing the boundaries of biotechnology to bring transformative solutions to healthcare, driving forward a future where targeted and effective probiotictherapies revolutionize the treatment landscape. ”
Our first product, which has nearly completed preclinical development, is BT-PYL1. This product is a probiotic with a guidance system to kill the bacteria Helicobacter pylori. H. pylori is one of the most prevalent infections in the world, with multidrug resistant strains increasing which has led for a need for a different therapeutic strategy from antibiotics. BT-PYL1 has been shown to directly kill H. pylori in an animal challenge model, thereby having the potential of ameliorating H. pylori-induced gastritis and its associated risks, such as peptic ulcer disease and gastric adenocarcinoma.
Additionally, this approach could enhance the efficacy of standard H. pylori eradication therapy, which typically includes a combination of antibiotics and a proton pump inhibitor. Furthermore, BT-PYL1 could be used for multi-drug resistant infections and mitigate the adverse effects associated with antibiotic therapy, such as gastrointestinal disturbances, thereby improving patient adherence to treatment at a similar cost to current standard of care.
Our third product in the design development stage BT-SAL1, is a probiotic that has a guidance system to kill Salmonella. Salmonella is not only a burden in human diseases but is a huge burden in the bovine livestock industry. As this can be taken as a preventative it has numerous cost-effective advantages over current mainstream eradication methods.
Our second product currently in late preclinical development is BT-STA2 which is a probiotic with a guidance system to kill taphylococcus bacteria. A safe product which could be used by patients prior to elective surgery or by hospital staff to minimize hospital acquired Golden Staph infections – a huge burden to governments and people alike. Furthermore, Staph also causes various diseases in human and pets where this product could be used for either prevention or treatment.
The fourth product, also in the design development, BT-ONC1 is a probiotic that has a guidance system that delivers a proprietary anti-cancer peptide to colorectal cancer. The product could be taken as a preventative or taken following surgical removal of primary cancer.